ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0713

Significance of Persistent Hematuria in Childhood IgAN

Session Information

Category: Pediatric Nephrology

  • 1900 Pediatric Nephrology

Authors

  • Shima, Yuko, Wakayama Kenritsu Ika Daigaku, Wakayama, Wakayama Prefecture, Japan
  • Mukaiyama, Hironobu, Wakayama Kenritsu Ika Daigaku, Wakayama, Wakayama Prefecture, Japan
  • Tanaka, Yu, Wakayama Kenritsu Ika Daigaku, Wakayama, Wakayama Prefecture, Japan
  • Shimabukuro, Wataru, Ryukyu Daigaku Igakubu Daigakuin Igaku Kenkyuka, Ginowan, Okinawa, Japan
  • Kaito, Hiroshi, Hyogo Kenritsu Kodomo Byoin, Kobe, Hyogo Prefecture, Japan
  • Tanaka, Ryojiro, Hyogo Kenritsu Kodomo Byoin, Kobe, Hyogo Prefecture, Japan
  • Nozu, Kandai, Kobe Daigaku, Kobe, Hyogo Prefecture, Japan
  • Iijima, Kazumoto, Kobe Daigaku, Kobe, Hyogo Prefecture, Japan
  • Tokuhara, Daisuke, Wakayama Kenritsu Ika Daigaku, Wakayama, Wakayama Prefecture, Japan
  • Yoshikawa, Norishige, Takatsuki Byoin, Takatsuki, Osaka Prefecture, Japan
  • Nakanishi, Koichi, Ryukyu Daigaku Igakubu Daigakuin Igaku Kenkyuka, Ginowan, Okinawa, Japan
Background

While proteinuria remission is the most significant predictive for kidney outcome in childhood IgA nephropathy (c-IgAN), the value of persistent hematuria in predicting outcomes in c-IgAN is still debated. The purpose of this study is to clarify the clinicopathological significance and determinants of persistent hematuria (red blood cell count ≥ 5 HPF).

Methods

From July 1976 to December 2022, there were 567 children with biopsy-proven IgAN at Kobe University and Wakayama Medical University. We investigated clinicopathological differences in 263 (46.4%) with hematuria remission and 304 (53.6%) with persistent hematuria.

Results

The c-IgAN patients with persistent hematuria were more detected by school screening program (82.6 vs.75.3%, p=.04), higher onset age (11.8 vs. 10.1 yrs, p<.0001), and showed longer duration from onset to kidney biopsy (9.3 vs. 6.3 months, p=.02), lower rate of proteinuria remission (14.8 vs. 86.3%, p<.0001), and shorter observation period (3 vs. 8 yrs, p<.0001). There was no significant difference in pathological findings and treatments. The kidney survival rate of persistent hematuria group was significantly lower than that of hematuria remission group (67.2 [95%CI: 41.4-85.6] vs. 98.7 [95%CI: 96.0-99.6] % at 15 years, p<.0001). The Cox regression analyses showed that both proteinuria remission (HR: 0.04 [95%CI: 0.005-0.29], p=.0015) and hematuria remission (HR:0.06 [95%CI: 0.05-0.28], p=.0003) were significantly related to kidney outcome respectively in univariate analyses, but that only proteinuria remission was significantly related (HR:0.10 [95%CI: 0.01-1.00], p=0.02) in multivariate analyses.

Conclusion

Regarding kidney outcome, proteinuria remission is more important than disappearance of hematuria.

Digital Object Identifier (DOI)